stoxline Quote Chart Rank Option Currency Glossary
  
Windtree Therapeutics, Inc. (WINT)
3.61  -0.12 (-3.22%)    07-19 11:05
Open: 3.7772
High: 3.7772
Volume: 1,550
  
Pre. Close: 3.73
Low: 3.5505
Market Cap: 2(M)
Technical analysis
2024-07-19 1:23:52 PM
Short term     
Mid term     
Targets 6-month :  4.53 1-year :  5.2
Resists First :  3.88 Second :  4.45
Pivot price 3.48
Supports First :  2.95 Second :  2.45
MAs MA(5) :  3.67 MA(20) :  3.43
MA(100) :  4.97 MA(250) :  11.9
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  46.9 D(3) :  48.6
RSI RSI(14): 52.2
52-week High :  30.05 Low :  2.89
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ WINT ] has closed below upper band by 38.8%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.85 - 3.87 3.87 - 3.89
Low: 3.61 - 3.63 3.63 - 3.66
Close: 3.63 - 3.67 3.67 - 3.71
Company Description

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

Headline News

Fri, 12 Jul 2024
Windtree Therapeutics, Inc. to Post FY2024 Earnings of ($2.38) Per Share, HC Wainwright Forecasts (NASDAQ:WINT) - American Banking and Market News

Thu, 11 Jul 2024
HC Wainwright Comments on Windtree Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:WINT) - Defense World

Wed, 10 Jul 2024
Q2 2024 Earnings Forecast for Windtree Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:WINT) - Defense World

Mon, 01 Jul 2024
Windtree Therapeutics secures new equity financing options - Investing.com

Tue, 07 May 2024
Windtree Therapeutics Regains Compliance with Nasdaq - GlobeNewswire

Mon, 22 Apr 2024
What made Windtree Therapeutics stock tank 20% on Monday? - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 4 (%)
Held by Institutions 9.2 (%)
Shares Short 47 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS 13.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 30.22
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -33.6 %
Return on Equity (ttm) -53.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -29.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -14 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio 0.27
PEG Ratio 0
Price to Book value 0.11
Price to Sales 0
Price to Cash Flow -0.16
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android